The "perfect storm" for anatabine went down the drain with Trump's choice of Scott Gottlieb to head the FDA, a win for BIG PHARMA, as he was their choice, and is a loss for RCPIQ, since he will likely continue the current drug approval process, prove safety and efficacy first, which is incredibly expensive and lengthy.
Jim O'Neill's "just prove safety, then let the marketplace and doctors determine efficacy" was ideal for anatabine.